KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
about
Social medicine in the twenty-first centuryEGFR/Met association regulates EGFR TKI resistance in breast cancerMolecular biology of lung cancer: clinical implicationsMolecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancersImpact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trialsSomatic mutations affect key pathways in lung adenocarcinomaBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsEpidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issuesOptimizing the management of advanced non-small-cell lung cancer: a personal viewReplacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responsesMucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar featuresAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainGene mutations in lung cancer: promising predictive factors for the success of molecular therapyBiomarkers and Targeted Therapy in Pancreatic CancerMolecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-CancerRoles of NOTCH1 as a Therapeutic Target and a Biomarker for Lung Cancer: Controversies and PerspectivesThe distinctive nature of adenocarcinoma of the lungFrom human genome to cancer genome: the first decadeK-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive ValueTargeted therapies in development for non-small cell lung cancerRole of molecular studies in the diagnosis of lung adenocarcinomaCIViC databaseK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactionsMolecular pathology of lung cancer: key to personalized medicine.Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clonesInhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancerOncogenic RIT1 mutations in lung adenocarcinoma.Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyondTargeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALKThe impact of the Cancer Genome Atlas on lung cancer.Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential targetMapping the hallmarks of lung adenocarcinoma with massively parallel sequencingInternational association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomaHigh frequency of BRAF V600E mutations in ameloblastoma
P2860
Q21563429-D20E167D-DBF4-4281-9D68-B06CCD92F569Q24338635-6C712E44-FC9A-4DF3-B1BC-9323D1F0D1ABQ24610335-F1743111-68B5-4CC4-9EF4-89A4BC1FCF03Q24611043-18AD38F4-4AD3-482B-807B-D46E2FA09F45Q24625201-083CF300-C271-40D8-894C-2DE0431BEF73Q24648102-7B2028B0-C64C-4CA8-A665-C83D1B8FABEDQ24649935-2A945584-2DB7-42B6-9301-8E763A1FCC00Q24653036-A2A4508E-0FA4-43A6-960D-7956810F622AQ24656144-1CDBF8A6-9FDF-4E98-9678-E219167B9AA2Q24658420-D510CA46-569F-46E0-AE91-1434B1960D75Q24683814-E420DDF1-AEB1-4927-9058-A3368BD2CB9AQ24794765-EDE1FE77-2186-484E-95EA-A9488F6FA624Q24809183-2830938B-E242-430E-84FA-B2BB9FB38063Q26752755-2FAB9913-6A6A-41C5-B657-3854A27078C3Q26771116-56C602BF-10F3-40FB-81ED-B8FBF9F844C6Q26778550-D6F98C10-5A56-42BC-B114-CA299C12ADECQ26781159-70E08FF0-73D7-4396-97AF-101EEC95E854Q26827640-75AF1E70-9047-453F-91A6-A5027F188EE3Q26829425-528171E8-BFE9-405A-B2DD-D6D958C667D5Q27022852-4D0F3246-170B-452C-A23A-F70660E8440EQ27023212-C85C58BD-D57B-497B-B431-46EAF6ED2B39Q27612411-9AE448C3-E30E-40EC-B274-0994C16DF6C4Q27680654-1847C78B-7402-43C4-8BD9-4376CF4B76A3Q27691299-16E9B87D-A131-4269-BE98-64BBCC9F762EQ27851448-87D87EFA-7304-4B5B-ADE8-F4E2B2275004Q27851527-CEFA44F2-618F-46E3-A3EC-BC68E9F14644Q27851654-CD8FB4AA-3657-4D28-8334-F2BAAC74E868Q27851674-2C8D70AF-7C2A-4419-8941-130995248F3DQ27851710-8EA416FD-AC13-4064-9A6B-1EED23CCCBBDQ27851860-1C335BDC-6F9A-4F71-958C-E64EAF4AB1BFQ27852235-28FA1229-66BF-45DB-B6EA-2659A074328FQ27852543-AFC57D3C-EFBC-4466-B13B-F8741F145019Q27852800-F6E1D5AF-2992-4766-A24E-B0B87BA07E9EQ28080730-090E602B-B65F-413B-92E6-59BD47601218Q28083446-3E799A9F-9EE4-48BB-B8F7-36F88B40AB24Q28084190-B50C98F7-76E4-4D3B-A8AB-BF2D2CF30AF2Q28271520-7C56668C-3FA4-4DD8-A760-93BA1FC1BA31Q28275103-C53A2705-1B05-45FE-945B-27371887657BQ28303718-F84AB9B9-6AD8-47DD-A704-AF283D2C7286Q28304785-886F39F4-96C1-4F7E-98E7-88AC71F43A56
P2860
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
@ast
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
@en
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
@en-gb
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
@nl
type
label
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
@ast
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
@en
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
@en-gb
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
@nl
altLabel
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
@en
prefLabel
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
@ast
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
@en
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
@en-gb
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
@nl
P2093
P2860
P50
P3181
P1433
P1476
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
@en
P2093
Gregory J Riely
Maureen F Zakowski
Robert T Heelan
Theresa Y Wang
Vincent A Miller
P2860
P3181
P356
10.1371/JOURNAL.PMED.0020017
P407
P577
2005-01-01T00:00:00Z